EcoDrugPlus

Estrogen Receptor 2b

Ensembl ID : ENSDARG00000034181
Gene Symbol: ESR2B
12 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSDARG00000004861
Gene Symbol: ESRRGA
4 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Exportin 1 (Crm1 Homolog, Yeast) A

Ensembl ID : ENSDARG00000078041
Gene Symbol: XPO1A
5 Cross references
227 Possible Orthologues:

Exportin 1 (Crm1 Homolog, Yeast) B

Ensembl ID : ENSDARG00000063229
Gene Symbol: XPO1B
31 Enzyme and pathways 5 Cross references
166 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSDARG00000040890
Gene Symbol: FDPS
4 Enzyme and pathways 5 Cross references
269 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSDARG00000101062
Gene Symbol: FDFT1
4 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSDARG00000099143
Gene Symbol: FNTA
11 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSDARG00000027916
Gene Symbol: FNTB
7 Enzyme and pathways 5 Cross references
204 Possible Orthologues:

Fibroblast Growth Factor Receptor 1-Like

Ensembl ID : ENSDARG00000104015
Gene Symbol: LOC569566
5 Cross references
205 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSDARG00000011027
Gene Symbol: FGFR1A
31 Enzyme and pathways 4 Cross references
205 Possible Orthologues:

Fibroblast Growth Factor Receptor 1b

Ensembl ID : ENSDARG00000011190
Gene Symbol: FGFR1B
5 Cross references
147 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSDARG00000058115
Gene Symbol: FGFR2
30 Enzyme and pathways 5 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).